RealFeedApp Participants improved scores by an average of 15.4 points
In a study of 250 adults with bipolar mania, the drug RAP-219 achieved a statistically significant improvement of 3.1 points on a 0 to 60 clinical scale compared to placebo.
- Field
- drugs and trials
- What they did
- Rapport Therapeutics demonstrated that its experimental drug RAP-219 improved symptoms in patients with bipolar mania by an average of 15.4 points on a clinical scale over three weeks, compared to 12.3 points for the placebo group.
- Why it matters
- The 3.1-point difference between the groups was statistically significant, which could serve as a stepping stone to a market valued at over a billion dollars.
#bipolar disorder#clinical trial#rap-219#rapport therapeutics
